The Migraine Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Migraine Drugs Market:
https://www.thebusinessresearchcompany.com/report/migraine-drugs-global-market-report
According to The Business Research Company’s Migraine Drugs Global Market Report 2024, The migraine drugs market size has grown strongly in recent years. It will grow from $5 billion in 2023 to $5.38 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to advancements in drug formulations, increased awareness and diagnosis, stress and lifestyle factors, expansion of generic drugs, emergence of cgrp inhibitors.
The migraine drugs market size is expected to see strong growth in the next few years. It will grow to $6.84 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to personalized medicine approaches, telemedicine and remote consultations, healthcare policy and insurance coverage, increasing global migraine burden, combination therapies. Major trends in the forecast period include targeted therapies, telemedicine and remote consultations, patient-centric approaches, digital therapeutics, biosimilars in migraine treatment, clinical research and trials.
The growing female population is expected to propel the growth of the migraine drugs market going forward. The female population refers to the total number of females in all age groups who are residents in each country or region during a specific period. The prevalence of migraines is significantly higher in the female population compared to males due to a combination of genetic, hormonal, and environmental factors. For instance, in 2022, according to the World Population Prospects 2022 shared by the United Nations, a US-based intergovernmental organization, the population of females in the world is estimated at 4.00 billion, representing 49.75% of the world population, and it is now expected that females will outnumber males by 2049. Therefore, the growing female population is driving the growth of the migraine drugs market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13484&type=smp
The migraine drugs market covered in this report is segmented –
1) By Drug Class: Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants
2) By Route of Administration: Oral, Injectable, Other Routes
3) By End-User: Hospitals And Clinics, Retail Pharmacy, Online Pharmacy, Other End Users
Major companies operating in the migraine drugs market are focused on developing innovative products, such as Zavzpret, to better serve patients and gain a competitive edge in the market. Zavzpret is a nasal spray medication developed for the acute treatment of migraines with or without aura in adults. For instance, in March 2023, Pfizer, a US-based pharmaceutical company, received approval from the Food and Drug Administration, a US-based federal agency, for Zavzpret. It is the first and only approved zavegepant (CGRP receptor antagonist) nasal spray for the acute treatment of migraine. It targets the calcitonin gene-related peptide (CGRP) and is designed for the acute treatment of migraine. The approval of Zavzpret provides a new treatment option for individuals with migraines, especially for those who have nausea and vomiting with migraine attacks and for those who can’t use triptans because of cardiovascular risks.
The migraine drugs market report table of contents includes:
1. Executive Summary
2. Migraine Drugs Market Characteristics
3. Migraine Drugs Market Trends And Strategies
4. Migraine Drugs Market – Macro Economic Scenario
5. Global Migraine Drugs Market Size and Growth
.
.
.
26. South America Migraine Drugs Market
27. Brazil Migraine Drugs Market
28. Middle East Migraine Drugs Market
29. Africa Migraine Drugs Market
30. Migraine Drugs Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Johnson & Johnson Services Inc
- Bayer AG
- Merck & Co. Inc
- AbbVie Inc
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
